In this issue:
CheckMate 816: neoadjuvant nivolumab beneficial for operable NSCLC
Treatment durations from antiangiogenic drugs after anti-EGFR therapy for CRC
Adebrelimab is a novel PD-L1 antagonist for extensive-stage SCLC
Results from the first phase 2 trial of an anti-TIGIT antibody in NSCLC
Total neoadjuvant chemoradiotherapy efficacious for advanced rectal cancer
Temozolomide plus immune checkpoint inhibition for MSS, MGMT-silenced CRC
FOLFOXIRI and bevacizumab for early-onset metastatic CRC
cfDNA may be a marker of response to ALK inhibitor therapy in NSCLC
Tumour budding is a prognostic factor in stage 3 colon cancer
KRAS, BRAF and MSI status prognostic in CRC peritoneal metastasis patients
Please login below to download this issue (PDF)